Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	poly(G) binding	HNRNPDL DAZAP1	5.35e-04	10	70	2	GO:0034046
GeneOntologyMolecularFunction	transcription coactivator activity	BCL9L ELOB KMT2C RERE ZMIZ1 ARID1A	6.74e-04	303	70	6	GO:0003713
GeneOntologyMolecularFunction	transcription coregulator activity	BCL9L ELOB KMT2C PIAS3 RERE ZMIZ1 RUNX1T1 ARID1A	7.63e-04	562	70	8	GO:0003712
GeneOntologyMolecularFunction	type II transforming growth factor beta receptor binding	TGFB2 TGFBR3	7.82e-04	12	70	2	GO:0005114
GeneOntologyMolecularFunction	beta-catenin binding	BCL9L TCF7L2 ESR1 CDHR5	8.38e-04	120	70	4	GO:0008013
Domain	DUF4599	SPATA31D4 SPATA31D3 SPATA31C2	9.92e-06	12	68	3	PF15371
Domain	DUF4599	SPATA31D4 SPATA31D3 SPATA31C2	9.92e-06	12	68	3	IPR027970
Domain	zf-MIZ	PIAS3 ZMIZ1	2.71e-04	7	68	2	PF02891
Domain	ZF_SP_RING	PIAS3 ZMIZ1	2.71e-04	7	68	2	PS51044
Domain	Znf_MIZ	PIAS3 ZMIZ1	3.61e-04	8	68	2	IPR004181
Domain	ZF_PHD_2	KMT2C BAZ2B PHF3 ASXL3	3.99e-04	95	68	4	PS50016
Domain	ZF_PHD_1	KMT2C BAZ2B PHF3 ASXL3	4.15e-04	96	68	4	PS01359
Domain	-	GATAD2A ESR1 RERE	1.17e-03	57	68	3	3.30.50.10
Domain	Znf_NHR/GATA	GATAD2A ESR1 RERE	1.23e-03	58	68	3	IPR013088
Domain	Znf_GATA	GATAD2A RERE	1.33e-03	15	68	2	IPR000679
Domain	GATA	GATAD2A RERE	1.33e-03	15	68	2	PF00320
Domain	GATA_ZN_FINGER_1	GATAD2A RERE	1.52e-03	16	68	2	PS00344
Domain	GATA_ZN_FINGER_2	GATAD2A RERE	1.52e-03	16	68	2	PS50114
Domain	PHD	KMT2C BAZ2B PHF3	2.58e-03	75	68	3	PF00628
Domain	Znf_PHD-finger	KMT2C BAZ2B PHF3	3.00e-03	79	68	3	IPR019787
Domain	PHD	KMT2C BAZ2B PHF3	4.19e-03	89	68	3	SM00249
Domain	Znf_PHD	KMT2C BAZ2B PHF3	4.46e-03	91	68	3	IPR001965
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	HIVEP3 KMT2C TCF7L2 DAZAP1 MAP1B FAM120C DTNA BICRA MINK1 HECTD4 SRCIN1 RERE ZMIZ1 ARID1A CLEC16A CEP170B	5.01e-08	1489	72	16	28611215
Pubmed	Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.	JCAD TCF7L2 AFF2 PIAS3 BICRA ESR1 FAM186B ZNF804A FHIP1A	2.66e-07	430	72	9	35044719
Pubmed	Comparative Application of BioID and TurboID for Protein-Proximity Biotinylation.	BCL9L KMT2C TMEM201 TCF7L2 DAZAP1 CLCN7 ZMIZ1 ARID1A NUP160	4.42e-07	457	72	9	32344865
Pubmed	Interaction network of human early embryonic transcription factors.	BCL9L KMT2C TCF7L2 BICRA ASXL3 RERE ZMIZ1 ARID1A	6.78e-07	351	72	8	38297188
Pubmed	H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids.	HNRNPDL ELOB KMT2C TMEM201 TCF7L2 GATAD2A BAZ2B PHF3 SF3A1 NOL9 ZFC3H1 ARID1A SF3A2	2.27e-06	1294	72	13	30804502
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	HIVEP3 KMT2C CLCN7 KALRN BICRA CTDP1 HECTD4 SHC1 ARHGAP17 IRS2 ARID1A CEP170B	2.64e-06	1105	72	12	35748872
Pubmed	RUNX1T1, a potential prognostic marker in breast cancer, is co-ordinately expressed with ERα, and regulated by estrogen receptor signalling in breast cancer cells.	ESR1 RUNX1T1	4.23e-06	2	72	2	34264479
Pubmed	Essential domains of the PRP21 splicing factor are implicated in the binding to PRP9 and PRP11 proteins and are conserved through evolution.	SF3A1 SF3A2	4.23e-06	2	72	2	8718683
Pubmed	Combined biochemical and electron microscopic analyses reveal the architecture of the mammalian U2 snRNP.	SF3A1 SF3A2	4.23e-06	2	72	2	10385517
Pubmed	KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function.	KMT2C ESR1	4.23e-06	2	72	2	29755131
Pubmed	Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation.	ESR1 SHC1	4.23e-06	2	72	2	11773443
Pubmed	Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression.	TGFB2 TGFBR3	1.27e-05	3	72	2	17999987
Pubmed	Beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling.	TGFB2 TGFBR3	1.27e-05	3	72	2	12958365
Pubmed	A role for Cajal bodies in the final steps of U2 snRNP biogenesis.	SF3A1 SF3A2	1.27e-05	3	72	2	15316075
Pubmed	Activation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by co-regulator PIAS3.	PIAS3 ESR1	1.27e-05	3	72	2	11429412
Pubmed	MiR-193b regulates early chondrogenesis by inhibiting the TGF-beta2 signaling pathway.	TGFB2 TGFBR3	1.27e-05	3	72	2	25728278
Pubmed	Betaglycan alters NFκB-TGFβ2 cross talk to reduce survival of human granulosa tumor cells.	TGFB2 TGFBR3	1.27e-05	3	72	2	23322721
Pubmed	Interaction domains and nuclear targeting signals in subunits of the U2 small nuclear ribonucleoprotein particle-associated splicing factor SF3a.	SF3A1 SF3A2	1.27e-05	3	72	2	21349847
Pubmed	Betaglycan blocks metastatic behaviors in human granulosa cell tumors by suppressing NFκB-mediated induction of MMP2.	TGFB2 TGFBR3	1.27e-05	3	72	2	25128652
Pubmed	The insulin-like growth factor-1 pathway mediator genes: SHC1 Met300Val shows a protective effect in breast cancer.	SHC1 IRS2	1.27e-05	3	72	2	15308584
Pubmed	Inhibition of insulin-like growth factor-I signaling by ethanol in neuronal cells.	SHC1 IRS2	1.27e-05	3	72	2	11505033
Pubmed	Estrogen receptor-alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells.	ESR1 IRS2	1.27e-05	3	72	2	12821935
Pubmed	The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane.	ESR1 SHC1	1.27e-05	3	72	2	14764897
Pubmed	Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity.	ESR1 SHC1	1.27e-05	3	72	2	16113100
Pubmed	Mammalian splicing factor SF1 interacts with SURP domains of U2 snRNP-associated proteins.	HNRNPDL SF3A1 SF3A2	1.27e-05	22	72	3	26420826
Pubmed	PRISMA and BioID disclose a motifs-based interactome of the intrinsically disordered transcription factor C/EBPα.	HNRNPDL ELOB KMT2C TCF7L2 GATAD2A DAZAP1 BAZ2B BICRA SF3A1 ARID1A SF3A2	1.60e-05	1103	72	11	34189442
Pubmed	Cullin 1 (CUL1) Promotes Primary Ciliogenesis through the Induction of Ubiquitin-Proteasome-Dependent Dvl2 Degradation.	BCL9L CCDC8 LRRIQ1 RUNX1T1 DENND3	1.65e-05	152	72	5	34299191
Pubmed	WW domains provide a platform for the assembly of multiprotein networks.	DAZAP1 SF3A1 GAS7 ARID1A SF3A2	1.76e-05	154	72	5	16055720
Pubmed	Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways.	TCF7L2 ESR1 IRS2	1.89e-05	25	72	3	18992263
Pubmed	Large-scale genotyping identifies 41 new loci associated with breast cancer risk.	TCF7L2 ESR1 ZMIZ1 NOBOX	1.94e-05	76	72	4	23535729
Pubmed	Cancer gene mutation frequencies for the U.S. population.	KMT2C ARID1A	2.53e-05	4	72	2	34645806
Pubmed	Human splicing factor SF3a, but not SF1, is essential for pre-mRNA splicing in vivo.	SF3A1 SF3A2	2.53e-05	4	72	2	15647371
Pubmed	A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells.	ESR1 SHC1	2.53e-05	4	72	2	20935677
Pubmed	Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart.	TGFB2 TGFBR3	2.53e-05	4	72	2	10092230
Pubmed	Endothelial angiogenesis is directed by RUNX1T1-regulated VEGFA, BMP4 and TGF-β2 expression.	TGFB2 RUNX1T1	2.53e-05	4	72	2	28640846
Pubmed	Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity.	PIAS3 ESR1	2.53e-05	4	72	2	15961505
Pubmed	Domains in human splicing factors SF3a60 and SF3a66 required for binding to SF3a120, assembly of the 17S U2 snRNP, and prespliceosome formation.	SF3A1 SF3A2	2.53e-05	4	72	2	11533230
Pubmed	TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling.	TGFB2 TGFBR3	2.53e-05	4	72	2	24161934
Pubmed	Defining the proximal interaction networks of Arf GTPases reveals a mechanism for the regulation of PLD1 and PI4KB.	HNRNPDL CCDC8 AFF2 MINK1 PODXL2 LYSMD4 CLEC16A SDK1 NUP160	3.21e-05	777	72	9	35844135
Pubmed	Reciprocal interaction between SIRT6 and APC/C regulates genomic stability.	CCDC8 PHF3 HECTD4 ZFC3H1 ARID1A NUP160 MAP3K4	3.59e-05	440	72	7	34244565
Pubmed	Genetic susceptibility to keloid disease: transforming growth factor beta receptor gene polymorphisms are not associated with keloid disease.	TGFB2 TGFBR3	4.21e-05	5	72	2	15009106
Pubmed	Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites.	TGFB2 TGFBR3	4.21e-05	5	72	2	8106553
Pubmed	Crystal structure of a beta-catenin/BCL9/Tcf4 complex.	BCL9L TCF7L2	4.21e-05	5	72	2	17052462
Pubmed	Comprehensive comparative homeobox gene annotation in human and mouse.	CDX1 NOBOX	4.21e-05	5	72	2	26412852
Pubmed	Myeloid translocation gene family members associate with T-cell factors (TCFs) and influence TCF-dependent transcription.	TCF7L2 RUNX1T1	4.21e-05	5	72	2	18039847
Pubmed	DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity.	HNRNPDL ELOB DAZAP1 PIAS3 PHF3 ZFC3H1 ARID1A	4.31e-05	453	72	7	29656893
Pubmed	Dynamic Protein Interactions of the Polycomb Repressive Complex 2 during Differentiation of Pluripotent Cells.	BCL9L ELOB KMT2C GATAD2A DAZAP1 ARID1A NUP160	5.37e-05	469	72	7	27634302
Pubmed	The RNA-mediated estrogen receptor α interactome of hormone-dependent human breast cancer cell nuclei.	BCL9L ELOB KMT2C FAM120C PHF3 ESR1 MINK1 NOL9 ZFC3H1 FHIP1A SF3A2 CEP170B	5.43e-05	1497	72	12	31527615
Pubmed	The soluble exoplasmic domain of the type II transforming growth factor (TGF)-beta receptor. A heterogeneously glycosylated protein with high affinity and selectivity for TGF-beta ligands.	TGFB2 TGFBR3	6.31e-05	6	72	2	7852346
Pubmed	A novel role for protein inhibitor of activated STAT (PIAS) proteins in modulating the activity of Zimp7, a novel PIAS-like protein, in androgen receptor-mediated transcription.	PIAS3 ZMIZ1	6.31e-05	6	72	2	20159969
Pubmed	Type III TGF-beta receptor-independent signalling of TGF-beta2 via TbetaRII-B, an alternatively spliced TGF-beta type II receptor.	TGFB2 TGFBR3	6.31e-05	6	72	2	11157754
Pubmed	Functional association of U2 snRNP with the ATP-independent spliceosomal complex E.	SF3A1 SF3A2	6.31e-05	6	72	2	10882114
Pubmed	Genome-wide association study for type 2 diabetes in Indians identifies a new susceptibility locus at 2q21.	TGFBR3 TCF7L2	6.31e-05	6	72	2	23209189
Pubmed	Decreased Anxiety-Related Behaviour but Apparently Unperturbed NUMB Function in Ligand of NUMB Protein-X (LNX) 1/2 Double Knockout Mice.	DTNA SRCIN1 CLEC16A CEP170B	8.26e-05	110	72	4	27889896
Pubmed	Genome-wide SNP genotyping study using pooled DNA to identify candidate markers mediating susceptibility to end-stage renal disease attributed to Type 1 diabetes.	IRS2 ZMIZ1	8.82e-05	7	72	2	19929986
Pubmed	Identification of two distinct functions for TGF-beta in early mouse development.	TGFB2 TGFBR3	8.82e-05	7	72	2	9921650
Pubmed	Effects of TGFbeta2 on wild-type and Tgfbr3 knockout mouse fetal testis.	TGFB2 TGFBR3	8.82e-05	7	72	2	23303681
Pubmed	Vitamin D deficiency causes airway hyperresponsiveness, increases airway smooth muscle mass, and reduces TGF-β expression in the lungs of female BALB/c mice.	TGFB2 TGFBR3	8.82e-05	7	72	2	24760528
Pubmed	Expression of TGF-beta s and their receptors during implantation and organogenesis of the mouse embryo.	TGFB2 TGFBR3	8.82e-05	7	72	2	7813789
Pubmed	Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II.	SHC1 IRS2	8.82e-05	7	72	2	18611262
Pubmed	Neuron-specific protein network mapping of autism risk genes identifies shared biological mechanisms and disease-relevant pathologies.	JCAD BCL9L MAP1B KALRN FAM120C DTNA MINK1 SRCIN1 CLEC16A CEP170B	1.16e-04	1139	72	10	36417873
Pubmed	ARIP3 (androgen receptor-interacting protein 3) and other PIAS (protein inhibitor of activated STAT) proteins differ in their ability to modulate steroid receptor-dependent transcriptional activation.	PIAS3 ESR1	1.17e-04	8	72	2	11117529
Pubmed	RACK1-mediated integration of adhesion and insulin-like growth factor I (IGF-I) signaling and cell migration are defective in cells expressing an IGF-I receptor mutated at tyrosines 1250 and 1251.	SHC1 IRS2	1.17e-04	8	72	2	15611085
Pubmed	Identification of motif-based interactions between SARS-CoV-2 protein domains and human peptide ligands pinpoint antiviral targets.	SPATA31D4 SPATA31D3 KMT2C KALRN PHF3	1.26e-04	233	72	5	37704626
Pubmed	Shotgun sequencing of the human transcriptome with ORF expressed sequence tags.	AFF2 KALRN ASXL3 ESR1 ZMIZ1 FHIP1A DENND3	1.48e-04	552	72	7	10737800
Pubmed	Crosstalk between the p190-B RhoGAP and IGF signaling pathways is required for embryonic mammary bud development.	ESR1 IRS2	1.51e-04	9	72	2	17662267
Pubmed	Identification of a link between Wnt/β-catenin signalling and the cell fusion pathway.	BCL9L TCF7L2	1.51e-04	9	72	2	22109522
Pubmed	The Nse5/6-like SIMC1-SLF2 complex localizes SMC5/6 to viral replication centers.	HNRNPDL GATAD2A DAZAP1 MAP1B BAZ2B PHF3 BICRA SF3A1 ARID1A	1.53e-04	954	72	9	36373674
Pubmed	Human transcription factor protein interaction networks.	BCL9L KMT2C CCDC8 TCF7L2 GATAD2A DTNA BICRA ESR1 RERE ZMIZ1 ARID1A	1.64e-04	1429	72	11	35140242
Pubmed	Identification and functional characterization of transcriptional activators in human cells.	JCAD KMT2C TCF7L2 GATAD2A BICRA ARID1A	1.79e-04	398	72	6	35016035
Pubmed	Spatiotemporal-resolved protein networks profiling with photoactivation dependent proximity labeling.	HNRNPDL DAZAP1 MAP1B BICRA SF3A1 SF3A2	1.81e-04	399	72	6	35987950
Pubmed	Aurora kinase-A overexpression in mouse mammary epithelium induces mammary adenocarcinomas harboring genetic alterations shared with human breast cancer.	TCF7L2 ESR1	1.88e-04	10	72	2	27624071
Pubmed	Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells.	ESR1 SHC1	1.88e-04	10	72	2	24051437
Pubmed	The core component of the mammalian SWI/SNF complex SMARCD3/BAF60c is a coactivator for the nuclear retinoic acid receptor.	ESR1 ARID1A	1.88e-04	10	72	2	17363140
Pubmed	A novel U2 and U11/U12 snRNP protein that associates with the pre-mRNA branch site.	SF3A1 SF3A2	1.88e-04	10	72	2	11500380
Pubmed	Large-scale characterization of HeLa cell nuclear phosphoproteins.	HNRNPDL PHF3 SF3A1 NAF1 MINK1 CTDP1 IRS2 RERE	1.98e-04	774	72	8	15302935
Pubmed	Transcription factor protein interactomes reveal genetic determinants in heart disease.	GATAD2A BAZ2B SF3A1 RUNX1T1 ARID1A NUP160	2.13e-04	411	72	6	35182466
Pubmed	SOCS-6 binds to insulin receptor substrate 4, and mice lacking the SOCS-6 gene exhibit mild growth retardation.	ELOB IRS2	2.30e-04	11	72	2	12052866
Pubmed	Proteomic Analysis of the EWS-Fli-1 Interactome Reveals the Role of the Lysosome in EWS-Fli-1 Turnover.	HNRNPDL BCL9L DAZAP1 BICRA ARHGAP17 ARID1A	2.54e-04	425	72	6	24999758
Pubmed	Human GW182 Paralogs Are the Central Organizers for RNA-Mediated Control of Transcription.	KMT2C GATAD2A ARID1A	2.54e-04	59	72	3	28813667
Pubmed	Wnt regulation: exploring Axin-Disheveled interactions and defining mechanisms by which the SCF E3 ubiquitin ligase is recruited to the destruction complex.	HNRNPDL ELOB DAZAP1 GLB1 MAP1B SF3A1 ARHGAP17 SF3A2	2.67e-04	809	72	8	32129710
Pubmed	Genome-wide analysis of multi-ancestry cohorts identifies new loci influencing intraocular pressure and susceptibility to glaucoma.	GAS7 NUP160	2.75e-04	12	72	2	25173106
Pubmed	Biophysical studies on interactions and assembly of full-size E3 ubiquitin ligase: suppressor of cytokine signaling 2 (SOCS2)-elongin BC-cullin 5-ring box protein 2 (RBX2).	ELOB FBXO31	2.75e-04	12	72	2	25505247
Pubmed	Accelerated failure time models provide a useful statistical framework for aging research.	SHC1 IRS2	2.75e-04	12	72	2	19007875
Pubmed	Synaptic GAP and GEF Complexes Cluster Proteins Essential for GTP Signaling.	KALRN PHF3 MINK1 SRCIN1 CEP170B	2.99e-04	281	72	5	28706196
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	JCAD DAZAP1 PIAS3 KALRN HECTD4 USP25 GAS7 ZFC3H1 ARID1A SF3A2	3.06e-04	1285	72	10	35914814
Pubmed	Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication.	HNRNPDL GATAD2A SF3A1 CTDP1 ARID1A	3.09e-04	283	72	5	18854154
Pubmed	Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis.	KMT2C ESR1	3.25e-04	13	72	2	21502505
Pubmed	Identification of novel genetic Loci associated with thyroid peroxidase antibodies and clinical thyroid disease.	KALRN RERE	3.25e-04	13	72	2	24586183
Pubmed	Suppressor of Cytokine Signaling (SOCS) 5 utilises distinct domains for regulation of JAK1 and interaction with the adaptor protein Shc-1.	ELOB SHC1	3.25e-04	13	72	2	23990909
Pubmed	Computational and experimental studies on human misshapen/NIK-related kinase MINK-1.	MAP1B MINK1	3.25e-04	13	72	2	15032605
Pubmed	Protein interaction network of the mammalian Hippo pathway reveals mechanisms of kinase-phosphatase interactions.	JCAD BCL9L IRS2 ARID1A NUP160 CEP170B	3.29e-04	446	72	6	24255178
Pubmed	Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis.	RERE ZMIZ1 ZNF804A	3.39e-04	65	72	3	23453885
Pubmed	A bead-based approach for large-scale identification of in vitro kinase substrates.	HNRNPDL SF3A1 NAF1 ZFC3H1	3.73e-04	163	72	4	22113938
Pubmed	Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos.	TGFB2 TGFBR3	3.78e-04	14	72	2	12773577
Pubmed	A genome-wide association study of optic disc parameters.	TGFBR3 RERE	3.78e-04	14	72	2	20548946
Pubmed	MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons.	ELOB MAP1B KALRN SF3A1 HECTD4 PODXL2 ARID1A SF3A2 PLXNB1	3.88e-04	1082	72	9	38697112
Pubmed	Identifications of novel host cell factors that interact with the receptor-binding domain of the SARS-CoV-2 spike protein.	GLB1 MAP1B MINK1 NOL9 CLEC16A DENND3 PLXNB1	3.97e-04	650	72	7	38777146
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	JCAD CCDC8 MAP1B PHF3 MINK1 ARHGAP17 IRS2 CEP170B	4.04e-04	861	72	8	36931259
Pubmed	A multilocus candidate approach identifies ACE and HIF1A as susceptibility genes for cellulite.	TGFB2 ESR1	4.36e-04	15	72	2	20059631
Interaction	NUP35 interactions	HIVEP3 BCL9L KMT2C TMEM201 TCF7L2 DAZAP1 ESR1 ZMIZ1 ARID1A NUP160	1.72e-06	424	69	10	int:NUP35
Interaction	ERG interactions	HNRNPDL KMT2C TCF7L2 PIAS3 BICRA RERE ARID1A	1.11e-05	223	69	7	int:ERG
Interaction	GSC interactions	BCL9L KMT2C TCF7L2 ASXL3 RERE	1.21e-05	87	69	5	int:GSC
Interaction	CEBPA interactions	TGFB2 HNRNPDL ELOB KMT2C CDX1 TCF7L2 GATAD2A DAZAP1 BAZ2B BICRA SF3A1 ESR1 ARID1A SF3A2 NUP160	1.61e-05	1245	69	15	int:CEBPA
Interaction	CRX interactions	BCL9L KMT2C TCF7L2 BICRA RERE ZMIZ1 ARID1A	2.58e-05	254	69	7	int:CRX
Interaction	EGR2 interactions	BCL9L KMT2C TCF7L2 BICRA RERE ARID1A	2.63e-05	171	69	6	int:EGR2
Interaction	TLE3 interactions	TGFB2 BCL9L TCF7L2 BAZ2B ESR1 RERE ZMIZ1 ARID1A	4.22e-05	376	69	8	int:TLE3
Interaction	TBR1 interactions	BCL9L KMT2C TCF7L2 ZMIZ1 ARID1A	4.28e-05	113	69	5	int:TBR1
Interaction	RAC1 interactions	CCDC8 TCF7L2 DAZAP1 PIAS3 CLCN7 KALRN DTNA ESR1 MINK1 ARHGAP17 NUP160 PLXNB1 MAP3K4	5.58e-05	1063	69	13	int:RAC1
Interaction	SNRNP40 interactions	HNRNPDL BCL9L GATAD2A DAZAP1 BAZ2B SF3A1 NOL9 ZFC3H1 ARID1A SF3A2	5.87e-05	637	69	10	int:SNRNP40
Interaction	SP7 interactions	BCL9L KMT2C TCF7L2 BICRA RERE ZMIZ1 ARID1A	8.04e-05	304	69	7	int:SP7
Interaction	SAR1A interactions	AFF2 DAZAP1 DTNA PODXL2 LYSMD4 CLEC16A NUP160	1.22e-04	325	69	7	int:SAR1A
Interaction	NCBP2 interactions	CCDC8 SF3A1 ESR1 ZFC3H1 SF3A2	1.22e-04	141	69	5	int:NCBP2
Interaction	AR interactions	BCL9L KMT2C TCF7L2 DAZAP1 PIAS3 PHF3 ESR1 HECTD4 SHC1 RERE ZMIZ1 ARID1A	1.24e-04	992	69	12	int:AR
Interaction	AFDN interactions	ILDR2 JCAD CCDC8 DTNA ESR1 MINK1 SDK1	1.42e-04	333	69	7	int:AFDN
Interaction	BUB3 interactions	KMT2C MAP1B ASXL3 RERE ZFC3H1 SF3A2	1.43e-04	232	69	6	int:BUB3
GeneFamily	Zinc fingers MIZ-type	PIAS3 ZMIZ1	1.10e-04	7	42	2	85
GeneFamily	GATA zinc finger domain containing\|Myb/SANT domain containing	GATAD2A RERE	5.43e-04	15	42	2	82
GeneFamily	PHD finger proteins	KMT2C BAZ2B PHF3	1.19e-03	90	42	3	88
Coexpression	HALLMARK_UV_RESPONSE_DN	TGFBR3 PIAS3 MAP1B KALRN PHF3 ZMIZ1	2.64e-06	144	71	6	M5942
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_DN	TGFB2 HNRNPDL TGFBR3 TCF7L2 MAP1B BAZ2B PHF3 ZMIZ1 ZNF804A CLEC16A NUP160 MAP3K4	2.97e-06	856	71	12	M4500
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN	TGFB2 HNRNPDL TCF7L2 MAP1B BAZ2B PHF3 ZMIZ1 ZNF804A CLEC16A	4.61e-06	466	71	9	M13522
CoexpressionAtlas	DevelopingKidney_e14.5 whole kidney - Wnt4 KO_emap-6674_k-means-cluster#5_top-relative-expression-ranked_500	CCDC8 SHC1 PODXL2 RUNX1T1	9.82e-06	42	68	4	gudmap_developingKidney_e14.5 whole kidney - Wnt4 KO_500_k5
ToppCell	Fetal_brain-fetalBrain_Zhong_nature-GW26-Neuronal-GABAergic_neurons\|GW26 / Sample Type, Dataset, Time_group, and Cell type.	HIVEP3 MAP1B KALRN ASXL3 GAS7 SRCIN1 RUNX1T1 SDK1	1.24e-09	200	72	8	bad32a95b759fad509401b07bc96a56687c2a592
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell-Podocyte\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ILDR2 TGFBR3 MAP1B PCARE ZNF804A	1.09e-05	180	72	5	d685fa2b013bc085dbef7c40956ed3043f83e483
ToppCell	5'-Parenchyma_lung-Endothelial-Lymphatic_EC-endothelial_cell_of_lymphatic_vessel-Lymphatic_EC_differentiating-Lymphatic_EC_differentiating_L.2.5.1.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	TGFBR3 MAP1B KALRN SHC1 RUNX1T1	1.18e-05	183	72	5	4d16bfbadf2cd13008c35e23dd2b5b4ecf92ee11
ToppCell	kidney_cells-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell-Podocyte\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ILDR2 TGFBR3 MAP1B PCARE ZNF804A	1.31e-05	187	72	5	24c2a3962da364e46e98abeab5f8234376fa26bb
ToppCell	kidney_cells-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell-Degenerative_Podocyte\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ILDR2 TGFBR3 MAP1B PCARE ZNF804A	1.49e-05	192	72	5	ef0aba777072429a6ab7dcfcc305673975946580
ToppCell	facs-Aorta-Heart-3m-Mesenchymal\|Aorta / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TGFB2 ILDR2 PODXL2 IRS2 PLXNB1	1.49e-05	192	72	5	0dc1f46e40346ed0b286e53b106a812441575100
ToppCell	kidney_cells-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ILDR2 TGFBR3 MAP1B PCARE ZNF804A	1.53e-05	193	72	5	3eaa0461618582a1754400624350d269d24e750a
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Ascending_Vasa_Recta_Endothelial_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	HIVEP3 JCAD TGFBR3 KALRN RUNX1T1	1.57e-05	194	72	5	b490fffc94f005dff9a34ce34d80ca776e3a1387
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DTNA ASXL3 GAS7 RUNX1T1 SDK1	1.57e-05	194	72	5	89b706af2b25991fc2707eb24f49ba6ff3ae01f7
ToppCell	droplet-Limb_Muscle-MUSCLE-30m-Mesenchymal\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TGFB2 TGFBR3 AFF2 MAP1B IRS2	1.61e-05	195	72	5	5c86fddd6d0530beecf45ea5ba6b823123847696
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MAP1B KALRN DTNA RUNX1T1 ZNF804A	1.65e-05	196	72	5	1522958a92e0126326a9f0d9fb1c5b5c50b001ea
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MAP1B KALRN DTNA RUNX1T1 ZNF804A	1.65e-05	196	72	5	1c8294014713684b50885e638668f2ce75f357f0
ToppCell	Mild\|World / Condition, Lineage, Cell class and cell subclass	KALRN PHF3 SF3A1 MINK1 SF3A2	1.69e-05	197	72	5	476b0d0389f9fcd4614f6bb1f494281f467f6730
ToppCell	Bronchial-NucSeq-Stromal\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	TGFBR3 MAP1B GAS7 RUNX1T1 SDK1	1.81e-05	200	72	5	389cc775c8419d90fb77cd794376d2160a7bf44e
ToppCell	PND01-03-samps-Mesenchymal-Myofibroblast-myofibroblast_-_mature_-_B\|PND01-03-samps / Age Group, Lineage, Cell class and subclass	TGFBR3 MAP1B GAS7 PODXL2	7.41e-05	138	72	4	8d70e64843f7c3be8ee4203cc126fdf1001f0df5
ToppCell	10x5'-Lung-Lymphocytic_T_CD4-T_CD4/CD8\|Lung / Manually curated celltypes from each tissue	LRRIQ1 FAM186B SDK1 PLXNB1	1.19e-04	156	72	4	10d191e29b16cae8238e8df6c0ff38882253f34e
ToppCell	TCGA-Ovary-Primary_Tumor-Ovarian_Carcinoma-Serous_Cystadenocarcinoma-5\|TCGA-Ovary / Sample_Type by Project: Shred V9	HECTD4 ARID1A FAM186B PLXNB1	1.51e-04	166	72	4	32d2eaf8a5d03881bf74d680825af2d5110b082d
ToppCell	3'-GW_trimst-2-LargeIntestine-Neuronal-Glial_immature-Glia_2_(ELN+)\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TGFB2 MAP1B GAS7 SRCIN1	1.58e-04	168	72	4	95dc690c1987b05685d36e6bb20eb79308696e30
ToppCell	droplet-Marrow-nan-24m-Lymphocytic-NK_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TGFBR3 TCF7L2 KALRN MINK1	1.58e-04	168	72	4	e979a4fbeb9f21048b47d69e6da75c57650697f2
ToppCell	3'-GW_trimst-1.5-LargeIntestine-Neuronal-neurons_A\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	FAM120C DTNA AK9 ITIH6	1.62e-04	169	72	4	606aa4ff25380d9470ec116ca86cd20f8b19587a
ToppCell	Endothelial-B-Donor_02\|World / lung cells shred on cell class, cell subclass, sample id	TGFBR3 MAP1B KALRN RUNX1T1	1.62e-04	169	72	4	8889c9e8af1ab0b093d57b69abd80b59b3461be9
ToppCell	3'-GW_trimst-1.5-LargeIntestine-Neuronal-neurons_A-Branch_A1_(iMN)\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	FAM120C DTNA AK9 ITIH6	1.62e-04	169	72	4	052aae2af5446a0de071d5dda5381b0b9a0ed54d
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_medulla-lymphatic_endothelial_cell_of_renal_medulla\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	HIVEP3 MAP1B KALRN GAS7	1.66e-04	170	72	4	dcc64b73134e89ae37990d4878813b86ce91dae9
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell-Podocyte\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ILDR2 TGFBR3 MAP1B PCARE	1.66e-04	170	72	4	60bbd738c12e64e483485586c30057304884f5a6
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Endothelial-lymphatic_endothelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	HIVEP3 MAP1B KALRN GAS7	1.66e-04	170	72	4	6035c92cd39c5ac54e7ec57d94888ee19f574639
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_medulla\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	HIVEP3 MAP1B KALRN GAS7	1.66e-04	170	72	4	c8c42eda44b61440c96b202e7f54650046eb95d3
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22-Myeloid-Monocytic-Nonclassical_Monocyte-Mono_c5-CD16\|Severe-critical_progression_d12-22 / Compartment, severity and other cell annotations on 10x 3' data (130k)	JCAD TMEM201 TCF7L2 ZNF804A	1.69e-04	171	72	4	87d652afbb375f8ee50e5faecf6085630cd2163c
ToppCell	COVID-19-kidney-PEC\|kidney / Disease (COVID-19 only), tissue and cell type	TGFB2 ILDR2 DTNA SDK1	1.73e-04	172	72	4	36a96714a0eb6ac438648135336c9791881ddadb
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Renal_corpuscle_epithelial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ILDR2 TGFBR3 PCARE ZNF804A	1.73e-04	172	72	4	6c17a1e586a72d1bd80c20c06370429c61dc9f85
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell-Podocyte\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ILDR2 TGFBR3 PCARE ZNF804A	1.73e-04	172	72	4	381ae1c3c07d0a424f43455ec571653b192a946a
ToppCell	COPD-Lymphoid-ILC_A\|Lymphoid / Disease state, Lineage and Cell class	ILDR2 BAZ2B CTDP1 GAS7	1.77e-04	173	72	4	4a0043b29f8ede5a74bdb38cbf2c70e12b25e130
ToppCell	facs-GAT-Fat-18m\|GAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ELOB CDX1 CDHR5 SF3A2	1.77e-04	173	72	4	515cb02f3eef86a1ff9a2b4b4f794373ed6633aa
ToppCell	Children_(3_yrs)-Mesenchymal-vascular_smooth_muscle_cell\|Children_(3_yrs) / Lineage, Cell type, age group and donor	AFF2 MAP1B KALRN RUNX1T1	1.77e-04	173	72	4	5416b092321c7d9b63f0418c60f2402a138355bf
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ILDR2 TGFBR3 PCARE ZNF804A	1.81e-04	174	72	4	dbdcdec08f1fc69fcdb5d8a6d78df8ef9c374d89
ToppCell	E16.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_airway-SCMF-SCMF_mature\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	TGFBR3 DTNA HECTD4 GAS7	1.85e-04	175	72	4	1d8aab491dcc27ea5dbfb6462d18ee280b21a05e
ToppCell	E16.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_airway-SCMF\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	TGFBR3 DTNA HECTD4 GAS7	1.85e-04	175	72	4	427a7ee92fe16a90625946492062d37aa0f7235b
ToppCell	kidney_cells-Adult_normal_reference-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_cortex\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	MAP1B KALRN SHC1 GAS7	1.93e-04	177	72	4	227d4f423b00be2e0c5797e2c5275d342e69a0f4
ToppCell	metastatic_Lymph_Node-Endothelial_cells\|metastatic_Lymph_Node / Location, Cell class and cell subclass	JCAD KALRN ASXL3 RUNX1T1	1.93e-04	177	72	4	71bf5d4bc67bda37a0499e5ec01af7dd5254041d
ToppCell	kidney_cells-Adult_normal_reference-Endothelial-lymphatic_endothelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	MAP1B KALRN SHC1 GAS7	1.93e-04	177	72	4	66ffa279147961080c104242a08b176e301d80e3
ToppCell	facs-Thymus-Epithelium-3m-Myeloid\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GAS7 ARHGAP17 IRS2 FHIP1A	1.93e-04	177	72	4	0e9e44119653abfd270e602e5e477a15e774638f
ToppCell	kidney_cells-Adult_normal_reference-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_cortex-lymphatic_endothelial_cell_of_renal_cortex\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	MAP1B KALRN SHC1 GAS7	1.93e-04	177	72	4	0cbf54608d2ba0a0500af142f2029fe5e118c3c2
ToppCell	facs-Thymus-Epithelium-3m-Myeloid-macrophage\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GAS7 ARHGAP17 IRS2 FHIP1A	1.93e-04	177	72	4	c2b8a3a149d70f77612759dea34df9e43953c566
ToppCell	facs-Thymus-Epithelium-3m-Myeloid-macrophage\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GAS7 ARHGAP17 IRS2 FHIP1A	1.93e-04	177	72	4	384f841aa7b2d05815af7885e481f5affc55d897
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Glutamatergic_Excit-Glut_E_(THEMIS)-Glut_D_(IT_RORB_THEMIS_LINC00507)_6-Exc_L5-6_THEMIS_TMEM233\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	TGFBR3 LRRIQ1 ZMIZ1 RUNX1T1	2.02e-04	179	72	4	747a32460b257fffca30527b56a74720eb9c12e4
ToppCell	ILEUM-non-inflamed-(7)_Lymphatics\|non-inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	JCAD TGFBR3 KALRN SHC1	2.02e-04	179	72	4	99777a8931356d1206b8ab22aaa1b1d5a600b809
ToppCell	5'-GW_trimst-2-SmallIntestine-Neuronal-Glial_immature-ENCC/glia_Progenitor\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TGFB2 DTNA GAS7 SRCIN1	2.15e-04	182	72	4	d6740bca2b974122b8451989365a94a81140afd1
ToppCell	Children_(3_yrs)-Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ILDR2 JCAD TGFBR3 KALRN	2.15e-04	182	72	4	a20017b6a4f9a6a29e090e4dbd7c02ed1495bd50
ToppCell	PND01-03-samps-Mesenchymal-Myofibroblast\|PND01-03-samps / Age Group, Lineage, Cell class and subclass	TGFBR3 MAP1B GAS7 RUNX1T1	2.15e-04	182	72	4	812dac35b9aa05be48258082e007f6c00e7b4dd8
ToppCell	COVID-19-kidney-Podocyte\|kidney / Disease (COVID-19 only), tissue and cell type	ILDR2 TGFBR3 MAP1B ZNF804A	2.20e-04	183	72	4	fb5e2a31b560126e1c04a386c24c365901c60ad7
ToppCell	wk_08-11-Epithelial-PNS-COL20A1+_Schwann\|wk_08-11 / Celltypes from embryonic and fetal-stage human lung	GAS7 SRCIN1 ITIH6 ZNF804A	2.29e-04	185	72	4	abec2a49fe0f0fa4cba49347207a1ee317333657
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-MatrixFB_->_Myofibroblast\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	TGFB2 TGFBR3 DTNA RUNX1T1	2.29e-04	185	72	4	6712512100ccef456d2e2bd201d0987986c92ac9
ToppCell	facs-Limb_Muscle-ForelimbandHindlimb\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	JCAD MAP1B ESR1 IRS2	2.29e-04	185	72	4	eb7d3c1363d5fedc611f9c1a91ea823de251355e
ToppCell	Control-Lymphoid-ILC_A\|Lymphoid / Disease state, Lineage and Cell class	ILDR2 CTDP1 GAS7 RERE	2.29e-04	185	72	4	520795866d44def5be3910ce8e728045c716a24d
ToppCell	Endothelial-B-Donor_07\|World / lung cells shred on cell class, cell subclass, sample id	TGFB2 MAP1B KALRN SHC1	2.29e-04	185	72	4	133c9dc64d564dae4aeeeca22f386aa3f13fa980
ToppCell	Ciliated_cells-A-Donor_04\|World / lung cells shred on cell class, cell subclass, sample id	ERICH3 LRRIQ1 MAP1B ASXL3	2.29e-04	185	72	4	d77ca57b02125a3a57a37f4aed20c89803b7d551
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L3-4_PVALB_HOMER3\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	AFF2 PCARE ZNF804A SDK1	2.34e-04	186	72	4	948815663c212c4311329d503b5991cbbbff9808
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Glutamatergic_Excit\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	LRRIQ1 KALRN ASXL3 DENND3	2.34e-04	186	72	4	84ba666237c18189d7e7556bd92dd953af733c00
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_3\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MAP1B KALRN DTNA SDK1	2.34e-04	186	72	4	4780af76237d7af2abbe2d8d5530cdf53e3ed0b7
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ILDR2 TGFBR3 MAP1B PCARE	2.34e-04	186	72	4	1094c7140131454b2583200e1c01e81ccab3db23
ToppCell	5'-Parenchyma_lung-Endothelial-Lymphatic_EC-endothelial_cell_of_lymphatic_vessel-Lymphatic_EC_differentiating\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	TGFBR3 MAP1B KALRN SHC1	2.34e-04	186	72	4	40070d9cd20188ba49b32acfca9bc16256b38bf5
ToppCell	pdx\|World / Sample and Cell Type and Tumor Cluster (all cells)	HECTD4 RERE ARID1A SDK1	2.34e-04	186	72	4	de8e538c8767d41b8a52f5e58ba1affd4e7244c4
ToppCell	pdx-Tumor_cells\|World / Sample and Cell Type and Tumor Cluster (all cells)	HECTD4 RERE ARID1A SDK1	2.34e-04	186	72	4	0b88a87158a9ca8de3bf40a4ff1687150707a5f0
ToppCell	Adult-Mesenchymal-matrix_fibroblast_1_cell-D175\|Adult / Lineage, Cell type, age group and donor	DTNA ASXL3 RUNX1T1 SDK1	2.38e-04	187	72	4	e15d2967aac248da3517bc2c7d1beaa1d5a0aa7f
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Endothelial-lymphatic_endothelial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MAP1B KALRN SHC1 GAS7	2.38e-04	187	72	4	65d406122dffe18279f14a1ed35ba091730b97be
ToppCell	COVID-19-Fibroblasts-Airway_smooth_muscle\|COVID-19 / group, cell type (main and fine annotations)	MAP1B KALRN DTNA SDK1	2.38e-04	187	72	4	464a0c3b92b778911b5f9cd73642e09e3472063a
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_cortex-lymphatic_endothelial_cell_of_renal_cortex\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MAP1B KALRN SHC1 GAS7	2.38e-04	187	72	4	4c15c0ed41a55271fc793cb76fee97fa64190369
ToppCell	COVID-19-kidney-Fibroblast-1\|COVID-19 / Disease (COVID-19 only), tissue and cell type	MAP1B KALRN ESR1 SDK1	2.38e-04	187	72	4	76bfe8c42430a230a8bdf299575c444fb7780f24
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_cortex\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MAP1B KALRN SHC1 GAS7	2.38e-04	187	72	4	5274f2b302bbf7fed30c480af4f35058d2cf61e0
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell-Degenerative_Podocyte\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ILDR2 TGFBR3 MAP1B PCARE	2.43e-04	188	72	4	9db778c1d9e622a68337212296e3a1ed8f771fa5
ToppCell	Control-Fibroblasts-Adventitial_FB\|Control / group, cell type (main and fine annotations)	TGFBR3 ESR1 GAS7 RUNX1T1	2.43e-04	188	72	4	706a26c372add839d947749f0521a0e1f5c9b0ec
ToppCell	10x3'2.3-week_14-16-Mesenchymal_fibro-stroma-endosteal_fibroblast\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	TGFB2 TGFBR3 RUNX1T1 SDK1	2.43e-04	188	72	4	0e2d1b21f0a7ee306e7dae16fc8c19d16a467883
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ILDR2 TGFBR3 MAP1B PCARE	2.43e-04	188	72	4	047c4e0b03fc8334e38c48977e41d26dbe229d47
ToppCell	E18.5-samps-Mesenchymal\|E18.5-samps / Age Group, Lineage, Cell class and subclass	TGFBR3 TCF7L2 GAS7 RUNX1T1	2.48e-04	189	72	4	0c18d3de4720759cf802eefb4d0ddde2a9246a1a
ToppCell	Neuroendocrine-neuroendo-2-Calca\|World / Class top	MAP1B ASXL3 PODXL2 RUNX1T1	2.48e-04	189	72	4	6baa9a74560121cc008bb8fa9b2b7a335b3aeee0
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_cortex\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	HIVEP3 MAP1B KALRN GAS7	2.53e-04	190	72	4	876bd2eb9ed2624cb23bdcf6b989e4fa34d099e3
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	MAP1B KALRN RUNX1T1 FAM186B	2.53e-04	190	72	4	1121eb607a984c59fbffe7220837fc178745aa55
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_cortex-lymphatic_endothelial_cell_of_renal_cortex\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	HIVEP3 MAP1B KALRN GAS7	2.53e-04	190	72	4	be9f36127028f52ca5fc1b32ba15a6c26aad69ac
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	MAP1B KALRN RUNX1T1 FAM186B	2.53e-04	190	72	4	048b581e3f7ea9fc2f87c0532974bba85c7292c2
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Endothelial-lymphatic_endothelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	HIVEP3 MAP1B KALRN GAS7	2.53e-04	190	72	4	09a8855901c3c9332dbaab3e40166485b696d0f1
ToppCell	(2)_Fibroblasts-(21)_Fibro-2\|(2)_Fibroblasts / Cell class and subclass of bone marrow stroma cells in homeostatis	ILDR2 PODXL2 CDHR5 SDK1	2.53e-04	190	72	4	d2afa08ad868acc6fce308ec21b0bf93591d4010
ToppCell	LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	HIVEP3 GAS7 RUNX1T1 SDK1	2.53e-04	190	72	4	45df8fee00f8949937863159d7aa042e72748d9b
ToppCell	Children_(3_yrs)-Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TGFB2 JCAD TGFBR3 KALRN	2.53e-04	190	72	4	0e9847d7f49b2236b8a191e1a7df37556351ba9e
ToppCell	Children_(3_yrs)-Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ILDR2 JCAD TGFBR3 KALRN	2.58e-04	191	72	4	f229abf69a1217194f74b0502486907e07dba989
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Ascending_Vasa_Recta_Endothelial_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	HIVEP3 JCAD TGFBR3 KALRN	2.58e-04	191	72	4	f663131a4810584c5854bd64ee7991a237b7707f
ToppCell	Control-Stromal-SMC\|Stromal / Disease state, Lineage and Cell class	MAP1B KALRN DTNA DENND3	2.58e-04	191	72	4	2da83c493e60ad0278848957645277d76737a188
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DTNA GAS7 RUNX1T1 SDK1	2.58e-04	191	72	4	b13229bb7f3713a392271aaf5dbae3edd1b9fe5a
ToppCell	Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_1_cell-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	HIVEP3 KALRN GAS7 SDK1	2.58e-04	191	72	4	08720998aa55131d7377c4c67c4c935865bd7d79
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	MAP1B KALRN ARHGAP17 RUNX1T1	2.58e-04	191	72	4	7b0d42a877540dbb346a76a62403e0d5d3e07fa6
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	MAP1B KALRN ARHGAP17 RUNX1T1	2.58e-04	191	72	4	cd854b9c426924fdc84bf7f411f6dea447143e79
ToppCell	3'-Child09-12-SmallIntestine-Neuronal-Glial_mature\|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TGFB2 MAP1B DTNA GAS7	2.64e-04	192	72	4	ac507fd7cf3b3e521a15ef03bb4e81eb23807985
ToppCell	human_hepatoblastoma-Tumor_cells\|World / Sample and Cell Type and Tumor Cluster (all cells)	PHF3 RERE ZFC3H1 SDK1	2.64e-04	192	72	4	916fbec1c7ab7969bda711886ac88e877e30c280
ToppCell	3'-Child09-12-SmallIntestine-Neuronal\|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TGFB2 MAP1B DTNA GAS7	2.64e-04	192	72	4	24f40dadec04f4f99c31000fa9f09d07148fa190
ToppCell	Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)\|World / Lineage, Cell type, age group and donor	ILDR2 JCAD TGFBR3 KALRN	2.64e-04	192	72	4	1e156bab5ecf64627890d2de9b27603d9a01f28d
ToppCell	3'-Child09-12-SmallIntestine-Neuronal-Glial_mature-Adult_Glia\|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TGFB2 MAP1B DTNA GAS7	2.64e-04	192	72	4	71e04e197825856c6d4278fc76c58ab17ffa2387
ToppCell	droplet-Limb_Muscle-MUSCLE-30m-Mesenchymal-mesenchymal_stem_cell\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TGFB2 TGFBR3 AFF2 IRS2	2.64e-04	192	72	4	11088878043a6ff95ba1970361256a82e434b80a
ToppCell	LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DTNA GAS7 RUNX1T1 SDK1	2.64e-04	192	72	4	deeecd26972241846b4cb998edf0c7a87ff0c4df
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	DTNA ASXL3 RUNX1T1 SDK1	2.69e-04	193	72	4	fb28717fadd06c3840636d25409ce80c9254bd34
ToppCell	Bronchial_Biopsy-Epithelial-Ciliated_1\|Epithelial / Tissue, Lineage and Cell class of Lung Cells from 10X	ERICH3 LRRIQ1 MAP1B AK9	2.69e-04	193	72	4	0b62a6ddd7c42efd9f39781971d1438501e1fa8d
ToppCell	LA\|World / Chamber and Cluster_Paper	TGFBR3 MAP1B GAS7 SDK1	2.69e-04	193	72	4	d4bf89437216baf489ea0239136dcedf3b6714af
ToppCell	LAM-Endothelial-LymEndo\|LAM / Condition, Lineage and Cell class	JCAD MAP1B KALRN SHC1	2.69e-04	193	72	4	68eadc91c2d89edd2412e86dfe134dd7c0ef6ee9
Drug	Withaferin A [5119-48-2]; Down 200; 1uM; MCF7; HT_HG-U133A	TGFB2 HIVEP3 TCF7L2 FAM120C ESR1 GAS7 RERE ZNF804A CDK10	5.65e-09	186	70	9	3902_DN
Drug	Gabazine [105538-73-6]; Down 200; 10.8uM; PC3; HT_HG-U133A	TCF7L2 FAM120C DTNA MINK1 CDK10 SF3A2 DENND3 PLXNB1	1.56e-07	196	70	8	4236_DN
Drug	Graveoline [485-61-0]; Down 200; 14.4uM; PC3; HT_HG-U133A	HIVEP3 FAM120C BICRA MINK1 CTDP1 RERE CDK10 PLXNB1	1.56e-07	196	70	8	4276_DN
Drug	Tolbutamide [64-77-7]; Down 200; 14.8uM; MCF7; HT_HG-U133A	TCF7L2 DTNA ESR1 CTDP1 IRS2 RERE ARID1A	1.94e-06	190	70	7	4362_DN
Drug	Cimetidine [51481-61-9]; Down 200; 15.8uM; MCF7; HT_HG-U133A	TGFB2 PHF3 BICRA ESR1 CTDP1 IRS2 RERE	2.15e-06	193	70	7	1464_DN
Drug	Metolazone [17560-51-9]; Down 200; 11uM; MCF7; HT_HG-U133A	TCF7L2 DTNA ESR1 MINK1 GAS7 ARID1A SF3A2	2.31e-06	195	70	7	1514_DN
Drug	Zomepirac sodium salt [64092-48-4]; Up 200; 12.8uM; PC3; HT_HG-U133A	AFF2 CLCN7 PHF3 DTNA MINK1 GAS7 RUNX1T1	2.39e-06	196	70	7	4479_UP
Drug	Mepenzolate bromide [76-90-4]; Down 200; 9.6uM; PC3; HT_HG-U133A	HIVEP3 JCAD CLCN7 FAM120C GAS7 PODXL2 ARID1A	2.47e-06	197	70	7	3748_DN
Drug	(+)-Isoproterenol (+)-bitartrate salt [14638-70-1]; Down 200; 11uM; PC3; HT_HG-U133A	JCAD CLCN7 SF3A1 MINK1 GAS7 ARID1A PLXNB1	2.47e-06	197	70	7	6663_DN
Drug	Minoxidil [38304-91-5]; Down 200; 19.2uM; MCF7; HT_HG-U133A	HIVEP3 TCF7L2 FAM120C PHF3 BICRA CEP170B PLXNB1	2.55e-06	198	70	7	4800_DN
Drug	arachidonic acid sodium salt; Up 200; 10uM; MCF7; HG-U133A	TGFB2 ELOB DTNA BICRA ESR1 CTDP1 RERE	2.55e-06	198	70	7	443_UP
Drug	Methylatropine nitrate [52-88-0]; Down 200; 11uM; MCF7; HT_HG-U133A	HIVEP3 FAM120C PHF3 ESR1 ZNF804A CLEC16A CDK10	2.64e-06	199	70	7	6495_DN
Drug	Aztreonam [78110-38-0]; Up 200; 9.2uM; MCF7; HT_HG-U133A	TGFB2 HIVEP3 JCAD DTNA ESR1 IRS2 CDK10	2.73e-06	200	70	7	5535_UP
Drug	isoprunetin 7-O-beta-D-glucopyranoside	GLB1 ESR1	9.32e-06	2	70	2	CID000189922
Drug	o,p'-dicofol	GLB1 ESR1	9.32e-06	2	70	2	CID000091566
Drug	2-chloro-4-nonylphenol	GLB1 ESR1	9.32e-06	2	70	2	CID000043176
Drug	Rifabutin [72559-06-9]; Down 200; 4.8uM; MCF7; HT_HG-U133A	DTNA ESR1 ARID1A CDK10 SF3A2 PLXNB1	2.19e-05	184	70	6	4349_DN
Drug	Mepenzolate bromide [76-90-4]; Up 200; 9.6uM; PC3; HT_HG-U133A	TGFB2 KALRN PHF3 DTNA SF3A1 MINK1	2.55e-05	189	70	6	4304_UP
Drug	Bupivacaine hydrochloride [18010-40-7]; Down 200; 12.4uM; MCF7; HT_HG-U133A	GATAD2A DAZAP1 MAP1B DTNA ESR1 CDK10	2.70e-05	191	70	6	7435_DN
Drug	Acetohexamide [968-81-0]; Up 200; 12.4uM; PC3; HT_HG-U133A	HNRNPDL CDX1 CLCN7 ESR1 MINK1 ARID1A	2.79e-05	192	70	6	1829_UP
Drug	licoflavone	GLB1 ESR1	2.79e-05	3	70	2	CID005319000
Drug	STOCK1N-28457; Down 200; 20uM; MCF7; HT_HG-U133A	HIVEP3 TCF7L2 DTNA ESR1 MINK1 GAS7	2.87e-05	193	70	6	6869_DN
Drug	Oxymetazoline hydrochloride [2315-02-8]; Down 200; 13.4uM; PC3; HT_HG-U133A	TGFBR3 CLCN7 PHF3 ESR1 CTDP1 CDK10	2.87e-05	193	70	6	2114_DN
Drug	Carbarsone [121-59-5]; Up 200; 15.4uM; MCF7; HT_HG-U133A	TGFBR3 CLCN7 PHF3 ESR1 MINK1 RERE	2.87e-05	193	70	6	3250_UP
Drug	(d,l)-Tetrahydroberberine [522-97-4]; Down 200; 11.8uM; MCF7; HT_HG-U133A	TGFB2 AFF2 CLCN7 ESR1 PODXL2 RUNX1T1	2.87e-05	193	70	6	4138_DN
Drug	Hycanthone [3105-97-3]; Down 200; 11.2uM; MCF7; HT_HG-U133A	TCF7L2 MAP1B DTNA ESR1 PODXL2 NUP160	2.87e-05	193	70	6	3229_DN
Drug	Y-27632; Up 200; 3uM; MCF7; HT_HG-U133A_EA	TGFB2 MAP1B DTNA BICRA CTDP1 GAS7	2.87e-05	193	70	6	948_UP
Drug	Butoconazole nitrate [32872-77-1]; Down 200; 8.4uM; HL60; HT_HG-U133A	ELOB TCF7L2 PIAS3 DTNA ESR1 CEP170B	2.95e-05	194	70	6	2427_DN
Drug	Pimozide [2062-78-4]; Up 200; 8.6uM; PC3; HT_HG-U133A	DTNA ESR1 CTDP1 IRS2 DENND3 PLXNB1	2.95e-05	194	70	6	7132_UP
Drug	Chicago sky blue 6B [2610-05-1]; Up 200; 4uM; PC3; HT_HG-U133A	TGFB2 PHF3 DTNA GAS7 RUNX1T1 ARID1A	3.04e-05	195	70	6	6626_UP
Drug	Carbimazole [22232-54-8]; Down 200; 21.4uM; MCF7; HT_HG-U133A	TGFBR3 FAM120C DTNA CTDP1 IRS2 ZNF804A	3.04e-05	195	70	6	5399_DN
Drug	cox-2 inhibitor I; Up 200; 10uM; MCF7; HG-U133A	AFF2 CLCN7 DTNA ESR1 DENND3 PLXNB1	3.04e-05	195	70	6	207_UP
Drug	Mephenytoin [50-12-4]; Down 200; 18.4uM; MCF7; HT_HG-U133A	HIVEP3 MAP1B GAS7 IRS2 CDK10 PLXNB1	3.04e-05	195	70	6	3580_DN
Drug	Sulfapyridine [144-83-2]; Down 200; 16uM; MCF7; HT_HG-U133A	TGFB2 TGFBR3 CLCN7 DTNA GAS7 IRS2	3.04e-05	195	70	6	6101_DN
Drug	Brinzolamide [138890-62-7]; Down 200; 10.4uM; PC3; HT_HG-U133A	TGFB2 SF3A1 GAS7 IRS2 ARID1A PLXNB1	3.04e-05	195	70	6	6670_DN
Drug	Benzbromarone [3562-84-3]; Down 200; 9.4uM; MCF7; HT_HG-U133A	TGFB2 TCF7L2 CLCN7 MINK1 CTDP1 IRS2	3.13e-05	196	70	6	5015_DN
Drug	Aminopurine, 6-benzyl [1214-39-7]; Down 200; 17.8uM; PC3; HT_HG-U133A	FAM120C DTNA MINK1 PODXL2 RERE CDK10	3.13e-05	196	70	6	3726_DN
Drug	Cotinine (-) [486-56-6]; Down 200; 22.6uM; MCF7; HT_HG-U133A	MAP1B DTNA ESR1 MINK1 GAS7 ARID1A	3.13e-05	196	70	6	1511_DN
Drug	Tranylcypromine hydrochloride [1986-47-6]; Up 200; 23.6uM; PC3; HT_HG-U133A	JCAD TCF7L2 PHF3 DTNA ARID1A NUP160	3.13e-05	196	70	6	2101_UP
Drug	Oxantel pamoate [68813-55-8]; Up 200; 6.6uM; MCF7; HT_HG-U133A	TCF7L2 CLCN7 MAP1B FAM120C ESR1 ARHGAP17	3.13e-05	196	70	6	5338_UP
Drug	Diflorasone Diacetate [33564-31-7]; Down 200; 8uM; MCF7; HT_HG-U133A	CTDP1 ARHGAP17 IRS2 CDK10 CEP170B MAP3K4	3.22e-05	197	70	6	4158_DN
Drug	15(S)-15-methyl Prostaglandin E2; Up 200; 10uM; MCF7; HT_HG-U133A	HIVEP3 ESR1 CTDP1 GAS7 RUNX1T1 SF3A2	3.22e-05	197	70	6	7521_UP
Drug	Glipizide [29094-61-9]; Down 200; 9uM; MCF7; HT_HG-U133A	MAP1B DTNA MINK1 CTDP1 GAS7 IRS2	3.22e-05	197	70	6	1508_DN
Drug	Norgestrel-(-)-D [797-63-7]; Down 200; 12.8uM; MCF7; HT_HG-U133A	TGFB2 AFF2 ESR1 MINK1 GAS7 RERE	3.22e-05	197	70	6	4730_DN
Drug	rosiglitazone; Down 200; 10uM; MCF7; HT_HG-U133A_EA	TCF7L2 ESR1 CTDP1 PODXL2 IRS2 SF3A2	3.22e-05	197	70	6	1013_DN
Drug	Sulfadiazine [68-35-9]; Down 200; 16uM; PC3; HT_HG-U133A	TCF7L2 CLCN7 BICRA NUP160 CEP170B DENND3	3.22e-05	197	70	6	1810_DN
Drug	Norethindrone [68-22-4]; Down 200; 13.4uM; MCF7; HT_HG-U133A	TCF7L2 DTNA ESR1 CDK10 SF3A2 NUP160	3.22e-05	197	70	6	7414_DN
Drug	NU1025; Up 200; 100uM; MCF7; HG-U133A	HIVEP3 ELOB CLCN7 PHF3 GAS7 DENND3	3.22e-05	197	70	6	313_UP
Drug	aspirin, USP; Down 200; 100uM; MCF7; HT_HG-U133A	TGFB2 GATAD2A FAM120C DTNA PODXL2 CDK10	3.22e-05	197	70	6	5564_DN
Drug	Nifuroxazide [965-52-6]; Up 200; 14.6uM; HL60; HT_HG-U133A	AFF2 ESR1 MINK1 RERE ARID1A CEP170B	3.22e-05	197	70	6	2490_UP
Drug	Cloperastine hydrochloride [14984-68-0]; Down 200; 11uM; HL60; HT_HG-U133A	HIVEP3 TCF7L2 PHF3 DTNA ESR1 CDK10	3.31e-05	198	70	6	2549_DN
Drug	Tetramisole hydrochloride [16595-80-5]; Down 200; 16.6uM; HL60; HT_HG-U133A	ELOB TCF7L2 BICRA GAS7 RERE CDK10	3.31e-05	198	70	6	2489_DN
Drug	Cephapirin sodium salt [24356-60-3]; Down 200; 9uM; HL60; HT_HG-U133A	TCF7L2 FAM120C PHF3 DTNA MINK1 RERE	3.31e-05	198	70	6	2730_DN
Drug	Chlorhexidine [55-56-1]; Down 200; 8uM; MCF7; HT_HG-U133A	TCF7L2 CLCN7 PHF3 DTNA GAS7 ARID1A	3.31e-05	198	70	6	1525_DN
Drug	Boldine [476-70-0]; Down 200; 12.2uM; PC3; HT_HG-U133A	CLCN7 MAP1B DTNA BICRA CTDP1 GAS7	3.31e-05	198	70	6	4004_DN
Drug	Thiocolchicoside [602-41-5]; Up 200; 7uM; MCF7; HT_HG-U133A	TGFB2 AFF2 ESR1 CTDP1 IRS2 CDK10	3.31e-05	198	70	6	5520_UP
Drug	Tocainide hydrochloride; Down 200; 17.4uM; MCF7; HT_HG-U133A	TCF7L2 MAP1B FAM120C BICRA ESR1 ARID1A	3.31e-05	198	70	6	4838_DN
Drug	nordihydroguaiaretic acid; Down 200; 1uM; MCF7; HT_HG-U133A	HNRNPDL TCF7L2 BICRA MINK1 SF3A2 NUP160	3.40e-05	199	70	6	6942_DN
Drug	Dacarbazine [4342-03-4]; Down 200; 22uM; MCF7; HT_HG-U133A	CLCN7 BAZ2B BICRA ESR1 CDK10 SF3A2	3.40e-05	199	70	6	2754_DN
Drug	THIP Hydrochloride; Down 200; 22.6uM; MCF7; HT_HG-U133A	TCF7L2 CLCN7 PHF3 ESR1 IRS2 CDK10	3.40e-05	199	70	6	6511_DN
Drug	chlorpromazine hydrochloride; Down 200; 1uM; MCF7; HT_HG-U133A_EA	GATAD2A ESR1 PODXL2 IRS2 CLEC16A SF3A2	3.40e-05	199	70	6	997_DN
Drug	Levamisole hydrochloride [16595-80-5]; Down 200; 16.6uM; MCF7; HT_HG-U133A	HIVEP3 DTNA ESR1 MINK1 GAS7 SF3A2	3.40e-05	199	70	6	2257_DN
Drug	Clozapine [5786-21-0]; Down 200; 12.2uM; PC3; HT_HG-U133A	TGFB2 JCAD DTNA ESR1 CDK10 NUP160	3.40e-05	199	70	6	4670_DN
Drug	Mebhydroline 1,5-naphtalenedisulfonate [6153-33-9]; Down 200; 4.8uM; PC3; HT_HG-U133A	KALRN DTNA ESR1 MINK1 SF3A2 PLXNB1	3.40e-05	199	70	6	4211_DN
Drug	Verapamyl hydrochloride [152-11-4]; Down 200; 8.2uM; MCF7; HT_HG-U133A	TCF7L2 ESR1 CTDP1 GAS7 IRS2 PLXNB1	3.40e-05	199	70	6	1509_DN
Drug	genistein; Down 200; 1uM; MCF7; HG-U133A	CLCN7 ESR1 MINK1 GAS7 SF3A2 PLXNB1	3.40e-05	199	70	6	267_DN
Drug	Meropenem [96036-03-2]; Down 200; 10.4uM; MCF7; HT_HG-U133A	TGFB2 MAP1B PHF3 GAS7 CDK10 SF3A2	3.40e-05	199	70	6	3564_DN
Drug	Dibucaine [85-79-0]; Down 200; 11.6uM; MCF7; HT_HG-U133A	TCF7L2 CLCN7 PHF3 ESR1 CTDP1 IRS2	3.40e-05	199	70	6	1469_DN
Drug	Estriol [50-27-1]; Down 200; 13.8uM; MCF7; HT_HG-U133A	TGFB2 IRS2 ZNF804A CDK10 SF3A2 PLXNB1	3.40e-05	199	70	6	3563_DN
Drug	Flucytosine [2022-85-7]; Down 200; 31uM; PC3; HT_HG-U133A	HIVEP3 PHF3 MINK1 PODXL2 SF3A2 NUP160	3.50e-05	200	70	6	6690_DN
Drug	2-(ethylsulfonyl)ethanol	AFF2 DAZAP1 GLB1 SF3A1 RERE SF3A2	4.60e-05	210	70	6	CID000010549
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	TGFB2 HIVEP3 ESR1 ARID1A CDK10	1.65e-04	167	70	5	3979_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	BAZ2B ESR1 ZMIZ1 ARID1A MAP3K4	1.89e-04	172	70	5	7179_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	TCF7L2 ESR1 ARID1A CDK10 SF3A2	2.22e-04	178	70	5	4710_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	ESR1 ZMIZ1 ARID1A NUP160 MAP3K4	2.27e-04	179	70	5	5484_DN
Drug	trichostatin A; Down 200; 0.1uM; MCF7; HG-U133A	TGFB2 ESR1 ZMIZ1 ARID1A NUP160	2.27e-04	179	70	5	331_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	TGFB2 ESR1 ZMIZ1 ARID1A SF3A2	2.33e-04	180	70	5	5511_DN
Drug	Camptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; PC3; HT_HG-U133A	TCF7L2 PHF3 ZMIZ1 ARID1A MAP3K4	2.33e-04	180	70	5	4541_DN
Drug	LY 294002; Up 200; 10uM; PC3; HT_HG-U133A	TCF7L2 PHF3 IRS2 ARID1A CEP170B	2.39e-04	181	70	5	1236_UP
Drug	17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A_EA	ESR1 IRS2 ZFC3H1 CDK10 SF3A2	2.46e-04	182	70	5	947_DN
Drug	myrtenal	GLB1 IRS2	2.58e-04	8	70	2	ctd:C061545
Drug	LY 294002; Up 200; 10uM; MCF7; HT_HG-U133A	TCF7L2 BAZ2B ESR1 GAS7 IRS2	2.71e-04	186	70	5	6987_UP
Drug	chlorpromazine hydrochloride; Down 200; 1uM; MCF7; HT_HG-U133A	PHF3 DTNA MINK1 CTDP1 PODXL2	3.07e-04	191	70	5	5214_DN
Drug	Dimethisoquin hydrochloride [2773-92-4]; Up 200; 13uM; MCF7; HT_HG-U133A	TGFB2 TCF7L2 DTNA ESR1 IRS2	3.07e-04	191	70	5	4791_UP
Drug	Astemizole [68844-77-9]; Down 200; 8.8uM; PC3; HT_HG-U133A	TGFBR3 TCF7L2 DTNA ESR1 SF3A2	3.07e-04	191	70	5	4471_DN
Drug	Gabexate mesilate [56974-61-9]; Down 200; 9.6uM; HL60; HT_HG-U133A	HIVEP3 PIAS3 ESR1 MINK1 RERE	3.07e-04	191	70	5	2937_DN
Drug	Labetalol hydrochloride [32780-64-6]; Down 200; 11uM; MCF7; HT_HG-U133A	CLCN7 DTNA ESR1 CTDP1 SF3A2	3.14e-04	192	70	5	6809_DN
Drug	Pyrantel tartrate [33401-94-4]; Down 200; 11.2uM; HL60; HG-U133A	GATAD2A CLCN7 MINK1 ARID1A SF3A2	3.14e-04	192	70	5	1413_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; HL60; HT_HG-U133A	HIVEP3 TCF7L2 ARID1A ZNF804A CEP170B	3.14e-04	192	70	5	2450_DN
Drug	Proguanil hydrochloride [637-32-1]; Down 200; 13.8uM; MCF7; HT_HG-U133A	TGFB2 TCF7L2 MINK1 CDK10 PLXNB1	3.14e-04	192	70	5	3505_DN
Drug	Resveratrol [501-36-0]; Down 200; 17.6uM; MCF7; HT_HG-U133A	TGFB2 PHF3 DTNA BICRA ESR1	3.14e-04	192	70	5	2865_DN
Drug	Butylparaben [94-26-8]; Down 200; 20.6uM; MCF7; HT_HG-U133A	TGFBR3 TCF7L2 ESR1 MINK1 GAS7	3.22e-04	193	70	5	5608_DN
Drug	Flumethasone [2135-17-3]; Down 200; 9.8uM; PC3; HT_HG-U133A	HIVEP3 CLCN7 GAS7 PODXL2 SF3A2	3.22e-04	193	70	5	3712_DN
Drug	Triamcinolone [124-94-7]; Up 200; 10.2uM; PC3; HT_HG-U133A	MINK1 PODXL2 IRS2 SF3A2 DENND3	3.22e-04	193	70	5	2078_UP
Drug	Diethylstilbestrol [56-53-1]; Down 200; 15uM; HL60; HT_HG-U133A	TCF7L2 CLCN7 PHF3 BICRA ESR1	3.22e-04	193	70	5	2567_DN
Drug	Rapamycin; Up 200; 0.1uM; MCF7; HT_HG-U133A	CLCN7 FAM120C DTNA ESR1 PODXL2	3.22e-04	193	70	5	6981_UP
Drug	Progesterone [57-83-0]; Down 200; 12.8uM; PC3; HT_HG-U133A	BICRA RERE ARID1A SF3A2 DENND3	3.22e-04	193	70	5	6646_DN
Drug	Nifuroxazide [965-52-6]; Down 200; 14.6uM; PC3; HT_HG-U133A	HIVEP3 AFF2 DTNA CLEC16A PLXNB1	3.22e-04	193	70	5	4253_DN
Drug	Sulfacetamide sodic hydrate [6209-17-2]; Up 200; 15.8uM; PC3; HT_HG-U133A	HIVEP3 GATAD2A CLCN7 MAP1B IRS2	3.22e-04	193	70	5	1817_UP
Drug	Eucatropine hydrochloride [536-93-6]; Down 200; 12.2uM; MCF7; HT_HG-U133A	PHF3 DTNA ESR1 RERE CDK10	3.22e-04	193	70	5	3841_DN
Disease	Neurodevelopmental Disorders	HIVEP3 KMT2C TCF7L2 ASXL3 PLXNB1	2.67e-06	93	69	5	C1535926
Disease	attention deficit hyperactivity disorder, unipolar depression, bipolar disorder, autism spectrum disorder, schizophrenia	TCF7L2 RERE ZMIZ1 ZNF804A CDK10	4.02e-06	101	69	5	EFO_0003756, EFO_0003761, EFO_0003888, MONDO_0004985, MONDO_0005090
Disease	Colorectal Carcinoma	HIVEP3 KMT2C TCF7L2 MAP1B KALRN SF3A1 ZMIZ1 RUNX1T1 ARID1A ZNF804A	5.23e-06	702	69	10	C0009402
Disease	Klatskin's tumor (is_implicated_in)	KMT2C ARID1A	5.36e-05	5	69	2	DOID:4927 (is_implicated_in)
Disease	neutrophil percentage of leukocytes	KALRN BAZ2B MINK1 RERE ZMIZ1 ARID1A CLEC16A NUP160	8.79e-05	610	69	8	EFO_0007990
Disease	schizophrenia, type 2 diabetes mellitus	TCF7L2 GATAD2A RUNX1T1	1.41e-04	43	69	3	MONDO_0005090, MONDO_0005148
Disease	alcohol use disorder measurement	JCAD TCF7L2 HECTD4 RUNX1T1 ZNF804A	1.48e-04	214	69	5	EFO_0009458
Disease	body weight	TGFB2 TCF7L2 PHF3 ASXL3 ESR1 HECTD4 SPATA31C2 RUNX1T1 ITIH6 CDK10 NUP160	1.55e-04	1261	69	11	EFO_0004338
Disease	Carcinoma, Granular Cell	KMT2C TCF7L2 ESR1 ARID1A	1.61e-04	116	69	4	C0205644
Disease	Adenocarcinoma, Tubular	KMT2C TCF7L2 ESR1 ARID1A	1.61e-04	116	69	4	C0205645
Disease	Adenocarcinoma, Oxyphilic	KMT2C TCF7L2 ESR1 ARID1A	1.61e-04	116	69	4	C0205642
Disease	Carcinoma, Cribriform	KMT2C TCF7L2 ESR1 ARID1A	1.61e-04	116	69	4	C0205643
Disease	Adenocarcinoma, Basal Cell	KMT2C TCF7L2 ESR1 ARID1A	1.61e-04	116	69	4	C0205641
Disease	Adenocarcinoma	KMT2C TCF7L2 ESR1 ARID1A	1.61e-04	116	69	4	C0001418
Disease	intraocular pressure measurement	TGFB2 HIVEP3 JCAD TCF7L2 KALRN GAS7 NUP160	1.87e-04	509	69	7	EFO_0004695
Disease	loneliness measurement	TCF7L2 RERE ZNF804A NUP160	2.08e-04	124	69	4	EFO_0007865
Disease	wellbeing measurement	TCF7L2 BAZ2B ASXL3 NAF1 RERE ZNF804A SDK1 NUP160	2.08e-04	692	69	8	EFO_0007869
Disease	free androgen index	TGFB2 TCF7L2 ESR1 ZMIZ1 ARID1A NUP160	2.44e-04	374	69	6	EFO_0007005
Disease	basophil count, eosinophil count	HIVEP3 ELOB GLB1 RERE CLEC16A	2.56e-04	241	69	5	EFO_0004842, EFO_0005090
Disease	Endometrial Neoplasms	ESR1 ARID1A MAP3K4	3.44e-04	58	69	3	C0014170
Disease	pulse pressure measurement	HIVEP3 JCAD TGFBR3 TCF7L2 GATAD2A DAZAP1 MAP1B ESR1 FAM186B CLEC16A NUP160	3.64e-04	1392	69	11	EFO_0005763
Disease	unipolar depression	JCAD TCF7L2 ASXL3 ESR1 PCARE AK9 LYSMD4 RERE ZNF804A SDK1	4.75e-04	1206	69	10	EFO_0003761
Disease	Coronary Arteriosclerosis	JCAD ESR1 HECTD4	4.82e-04	65	69	3	C0010054
Disease	Coronary Artery Disease	JCAD ESR1 HECTD4	4.82e-04	65	69	3	C1956346
Disease	depressive symptom measurement	TCF7L2 ASXL3 RERE ZNF804A SDK1 NUP160	4.87e-04	426	69	6	EFO_0007006
Disease	acute graft vs. host disease, donor genotype effect measurement	KALRN SDK1	5.55e-04	15	69	2	EFO_0004599, EFO_0007892
Disease	T-Cell Lymphoma	ASXL3 ARID1A	6.33e-04	16	69	2	C0079772
Disease	pancreatitis	JCAD HECTD4	6.33e-04	16	69	2	EFO_0000278
Disease	Endometrial Carcinoma	ESR1 ARID1A MAP3K4	6.50e-04	72	69	3	C0476089
Disease	corneal resistance factor	TGFB2 TGFBR3 TCF7L2 FBXO31 ESR1 GAS7	6.56e-04	451	69	6	EFO_0010067
Disease	Tourette syndrome, schizophrenia	PHF3 RERE	8.05e-04	18	69	2	EFO_0004895, MONDO_0005090
Disease	age of onset of asthma	GLB1 RERE CLEC16A	8.52e-04	79	69	3	OBA_2001001
Disease	neuroticism measurement, wellbeing measurement, depressive symptom measurement	TCF7L2 SDK1	8.98e-04	19	69	2	EFO_0007006, EFO_0007660, EFO_0007869
Disease	monocyte count	HIVEP3 JCAD TGFBR3 TCF7L2 AFF2 KALRN BAZ2B CTDP1 IRS2 ZMIZ1	9.53e-04	1320	69	10	EFO_0005091
Disease	osteoporosis (biomarker_via_orthology)	ESR1 IRS2	1.21e-03	22	69	2	DOID:11476 (biomarker_via_orthology)
Disease	sensory peripheral neuropathy, remission	GAS7 RUNX1T1	1.32e-03	23	69	2	EFO_0009785, MONDO_0002321
Disease	Intrahepatic Cholangiocarcinoma	KMT2C ARID1A	1.44e-03	24	69	2	C0345905
Disease	Extrahepatic Cholangiocarcinoma	KMT2C ARID1A	1.44e-03	24	69	2	C3805278
Disease	Inhalant adrenergic use measurement	GLB1 RERE CLEC16A	1.50e-03	96	69	3	EFO_0009941
Disease	alcohol use disorder measurement, alcohol consumption measurement	TCF7L2 RUNX1T1 NUP160	1.54e-03	97	69	3	EFO_0007878, EFO_0009458
Disease	unipolar depression, schizophrenia	TCF7L2 ZNF804A	1.56e-03	25	69	2	EFO_0003761, MONDO_0005090
Disease	obesity (implicated_via_orthology)	TCF7L2 ESR1 SDK1 PLXNB1	1.64e-03	215	69	4	DOID:9970 (implicated_via_orthology)
Disease	platelet crit	JCAD GATAD2A KALRN IRS2 RERE ARID1A FHIP1A NUP160	1.67e-03	952	69	8	EFO_0007985
Disease	Antiglaucoma preparations and miotics use measurement	GAS7 NUP160	1.69e-03	26	69	2	EFO_0009944
Disease	Cholangiocarcinoma	KMT2C ARID1A	1.69e-03	26	69	2	C0206698
Disease	neurotic disorder	ASXL3 RERE ZNF804A	1.73e-03	101	69	3	EFO_0004257
Disease	Bone Diseases, Developmental	TGFB2 GLB1	1.82e-03	27	69	2	C0005941
Disease	Sezary Syndrome	KMT2C ARID1A	1.82e-03	27	69	2	C0036920
Disease	type 2 diabetes mellitus (implicated_via_orthology)	TCF7L2 AFF2 IRS2	1.93e-03	105	69	3	DOID:9352 (implicated_via_orthology)
Disease	TYPE 2 DIABETES MELLITUS	TCF7L2 IRS2	1.96e-03	28	69	2	125853
Disease	Type 2 diabetes mellitus	TCF7L2 IRS2	1.96e-03	28	69	2	cv:C0011860
Disease	neutrophil percentage of granulocytes	HIVEP3 GLB1 RERE CLEC16A	2.03e-03	228	69	4	EFO_0007994
Disease	age at first sexual intercourse measurement	TCF7L2 ESR1 RUNX1T1 ZNF804A SDK1	2.04e-03	383	69	5	EFO_0009749
Disease	lymphocyte count	JCAD TCF7L2 KALRN MINK1 HECTD4 RERE ZMIZ1 CLEC16A NUP160 DENND3	2.06e-03	1464	69	10	EFO_0004587
Disease	neuroticism measurement, cognitive function measurement	TCF7L2 KALRN ASXL3 RERE ARID1A ZNF804A	2.09e-03	566	69	6	EFO_0007660, EFO_0008354
Disease	Bilateral Wilms Tumor	ARID1A MAP3K4	2.10e-03	29	69	2	C2930471
Disease	eosinophil percentage of granulocytes	HIVEP3 GLB1 RERE CLEC16A	2.23e-03	234	69	4	EFO_0007996
Disease	opioid dependence	MAP1B CTDP1 ARHGAP17 SRCIN1	2.33e-03	237	69	4	EFO_0005611

Protein segments in the cluster

Peptide	Gene	Start	Entry
PPTALFHPMPVLPKA	CTDP1	751	Q9Y5B0
FHPMPVLPKAQPGPE	CTDP1	756	Q9Y5B0
NMPILSPHPPVGPKS	ERICH3	116	Q5RHP9
QPPQPPMAHDITATP	CDX1	221	P47902
PVDFPSPKPIPEEMQ	BAZ2B	1701	Q9UIF8
HPSAPMPPPSVVILN	AFF2	131	P51816
PMKEEQLFSPLPPSP	FAM186B	361	Q8IYM0
PSQPPEVPAHEMPTK	CEP170B	236	Q9Y4F5
SPTHDPKPAEAPMPA	CDHR5	731	Q9HBB8
PSPPPGPLHLVFNMK	DENND3	156	A2RUS2
APDMSKPPTAQPDFP	DAZAP1	331	Q96EP5
AHTMPNKALVHPPPP	ASXL3	2006	Q9C0F0
KLKHQMAEPLPPEPP	GOLGA8F;	81	Q08AF8
MEVPPRLSHVPPPLF	HNRNPDL	1	O14979
MEPKPDPFPQESPLD	NOBOX	396	O60393
PASHIAPAPVQPPMI	ARID1A	1621	O14497
PKPPAPEMNFLPSAA	GATAD2A	366	Q86YP4
LPKMNLVEPPWHMPP	PODXL2	146	Q9NZ53
LQPPMPKPLSPLHSL	NOL9	531	Q5SY16
PPDTPRPVMTDQFPK	KMT2C	1966	Q8NEZ4
KHMDPPPAPVQDRSP	MAP1B	2196	P46821
SHQPLLPAPPKTPMD	LYSMD4	196	Q5XG99
HPTPPPPQHYRLDDM	RUNX1T1	291	Q06455
IPIPLNERHSPKMPP	JCAD	246	Q9P266
DHPSKPVEKRLMPPP	GLB1	651	P16278
PDMDPPHPFPKEIPH	CLCN7	71	P51798
PPHDPHVDDPMRFKP	FBXO31	176	Q5XUX0
QPLNPEDPTMPFRHK	PLXNB1	1381	O43157
SPLMLLHPPPQLSPF	ESR1	106	P03372
PDEESHTPLPPPMKI	KALRN	1831	O60229
HTPLPPPMKIFDNDP	KALRN	1836	O60229
HVPPYPMKIAPPDGT	HECTD4	3936	Q9Y4D8
TPDFVPEPSPHDLPM	LRRIQ1	131	Q96JM4
LPSMHEYPLPPEPKS	IRS2	901	Q9Y4H2
GPPAPIDPPKHIQEM	FHIP1A	606	Q05DH4
EPFSSPPELPDVMKP	ELOB	91	Q15370
KPLPCEPELMPTFPH	CDK10	326	Q15131
NHMDITIPPLPPVAP	FAM120C	591	Q9NX05
PPAPAKPMHPENKLT	BCL9L	31	Q86UU0
LSKPETPNPHMPQTP	ITIH6	871	Q6UXX5
LHPMFPDQPEKPLNL	DTNA	316	Q9Y4J8
PPQPPGALSKPMSVH	BICRA	436	Q9NZM4
ARIMEKSTPHPPQPP	CCDC8	56	Q9H0W5
LMLPEEPPSAPPKNI	SDK1	761	Q7Z5N4
IPSPSPPMSPSQEHK	PCARE	1086	A6NGG8
PPMQRPVEPQEGPHK	MINK1	566	Q8N4C8
PMKVPRCHSDPPNPH	MAP3K4	1151	Q9Y6R4
YVPPLAPHPLPSADM	AK9	1691	Q5TCS8
KHPQDLASTPPPGPM	SPATA31C2	166	B4DYI2
PQPPTQATPLMHTKP	ARHGAP17	716	Q68EM7
FPHPDTMPEQQLLKP	GAS7	181	O60861
SMSHESPVLPPPQPL	SPATA31D4	536	Q6ZUB0
PFSMNANLPPPPALK	RERE	956	Q9P2R6
PPELDPLHPAANPME	RERE	1331	Q9P2R6
HPPPPMEDEPTSKKL	SF3A1	671	Q15459
MLHLSAAPPAPPPEV	NUP160	1	Q12769
HFKMEKPPAPPSLPA	SF3A2	211	Q15428
DAPMSPELPKPHLPD	CLEC16A	936	Q2KHT3
REVDMHPPLPQPVHP	PIAS3	111	Q9Y6X2
HPPLPQPVHPDVTMK	PIAS3	116	Q9Y6X2
IDMPPFFPSENAIPP	TGFB2	106	P61812
SMSHESPVLPPPQPL	SPATA31D3	536	P0C874
PKVQAADPAPPPTMF	SPEM2	431	Q0P670
KSVDFEMPPPSPPLN	SRCIN1	856	Q9C0H9
EMPPPSPPLNLHELS	SRCIN1	861	Q9C0H9
GMLMDKPHPPPLAPS	ILDR2	271	Q71H61
DPLAHLSMMPPPPAL	TCF7L2	541	Q9NQB0
PQHPLTPAFMSPGKP	HIVEP3	96	Q5T1R4
PFTQSRIPPDLPMHP	USP25	521	Q9UHP3
QSMFGFPPHLPPPLL	PHF3	1826	Q92576
SLFTMEPPHVPRKPP	TMEM201	566	Q5SNT2
PKEPFRSHPPSVRMP	ZFC3H1	106	O60293
MKPFEDALRVPPPPQ	SHC1	461	P29353
PSMKEPNPISPPIFH	TGFBR3	766	Q03167
VKPPFPPDIKPNMSA	ZMIZ1	536	Q9ULJ6
PPQMPIIPASVLHPS	ZNF804A	1166	Q7Z570
HQMAEPLPPEPPAVP	GOLGA8CP	281	A6NN73
LPVFDMHNFPLRPPP	NAF1	426	Q96HR8